360 Stem Cell & Regenerative Medicine Newsletter- April 16, 2015

 weSRCH's Best of the Internet Award

360 Stem Cell & Regenerative Medicine Newsletter - April 16, 2015

Featured Video: “Global Strategies- Finding Common Ground”

Commercialization secrets revealed! This unscripted, wide-ranging conversation of global thought leaders was one of most interesting sessions of the World Stem Cell Summit in San Antonio. The speakers included Chris Mason, MBBS, PhD, FRCS, University College London; Michael H. May, PhD, Centre for Commercialization of Regenerative Medicine (CCRM) and Avi Treves, PhD, Sheba Medical Center. Michael N. Druckman, of the global law firm Hogan Lovells expertly orchestrated the discussion.

World Stem Cell Summit

The Australian Business Review: US Giant Celgene Gives Mesoblast a $58m Shot in the Arm
“Celgene is its newest shareholder in Mesoblast. The biopharmaceutical company bought 15.3 million ordinary shares in Mesoblast for $58.5m at $3.82 per share. The share buy will see Celgene emerge with about a 4.5 percent stake in Mesoblast. The deal also includes Celgene earning a six-month right of first refusal over licensing deals for the commercialization of Mesoblast’s adult stem cell products in the treatment of certain diseases. This includes Mesoblast’s proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases and organ transplant rejection.”

Mayo Clinic

Want China Times: Taiwanese Team Makes Breakthrough in Retinal Cell Transplantation
Taiwanese scientists have developed a new technique for retinal cell transplantation that could one day result in more effective treatments for an incurable eye disease that in many cases leads to blindness. The method, which is currently being tested in pigs, could offer a new approach to dealing with age-related macular degeneration (AMD). The researchers devised a way to generate induced pluripotent stem cells from human blood and then arrange them on a customized stent no thicker than a human hair that is inserted under the retina.

Wake Forest

Morehead State University: MSU, Mayo Clinic Join Forces for “CDTX” Experiment- Stem Cells in Space
MSU along with the Mayo Clinic will team up for the “CDTX” innovative microgravity experiment funded by NASA. “The experiment will launch an edge-of space balloon test of a reentry capsule built by Terminal Velocity Aerospace, of Atlanta, Georgia, and will contain an exomedicine experiment designed by researchers at the Mayo Clinic using instrumentation built by MSU faculty and staff. The payload will assess the transportation of cryogenically-frozen adult stem cells as part of ongoing research in growth and harvesting stem cells in space.”


European Pharmaceutical Review: ReNeuron Files Application to Commence Phase I/II Clinical Trial with its Stem Cell Therapy Candidate for Retinitis Pigmentosa
“The proposed Phase I/II clinical trial will be conducted at Massachusetts Eye and Ear, Boston. The trial design is an open-label, dose escalation study to evaluate the safety, tolerability and preliminary efficacy of the hRPC stem cell therapy candidate in up to 15 patients with advanced RP. The method of administration of the hRPCs will be a single sub-retinal injection. The primary endpoint of the study is safety, with patients being followed up for 12 months post-treatment with monitoring including measurements of visual acuity.”


Medical Daily: Beyond Stem Cells? Regenerative Medicine Breakthrough Pushes COPD Treatment Forward, Marks Win For Method
“Scientists have found that regardless of their stage in life, lung cells are able to regenerate themselves in order to repair missing or damaged tissue. The team behind the discovery hopes that they will one day be able to replicate this natural behavior in order to help repair tissue damage in patients with conditions such as COPD. The new study is just one of many focusing on, not stem cells, but fully mature cells as a means of regrowing the human body.” The research team from Penn and Duke reported their findings in Nature Communications.


Cornell Chronicle: Encapsulated Stem Cells Accelerate Wound Healing
“Utilizing equine mesenchymal stromal cells, a team of Cornell scientists has shown that stem cells confined inside tiny capsules secrete substances that help heal simulated wounds in cell cultures, opening up new ways of delivering these substances to locations in the body where they can hasten healing. The capsules need to be tested to see if they help healing in animals and humans, but they could eventually lead to ‘living bandage’ technologies: wound dressings embedded with capsules of stem cells to help the wound regenerate.” The research was published in the journal Stem Cell Research & Therapy.


Springer Launches Regenerative Engineering and Translational Medicine
Springer has launched Regenerative Engineering and Translational Medicine in partnership with the newly formed Regenerative Engineering Society. The new international journal will cover the convergence of multiple fields, including tissue generation, advanced materials science, stem cell research, the physical sciences and developmental biology, and is actively seeking submissions.

TMC News: Texas Heart Institute Recruiting Patients with Peripheral Artery Disease for Adult Stem Cell Trial
“Doctors and researchers at the Texas Heart Institute (THI) are halfway to their goal of recruiting 80 patients who suffer from peripheral artery disease (PAD) for a new clinical trial to assess the benefits and risks in the use of adult stem cells from patients’ own bone marrow to treat leg pain commonly associated with the disease. PAD affects between 8 million and 10 million Americans. The primary leg symptom is called ‘intermittent claudication’, which can manifest as aching, cramps, numbness or feeling of fatigue in the leg muscles. These symptoms occur in approximately 1 million to 3 million sufferers of the disease.”


San Antonio Business Journal- StemBioSys Scores Major Funding
“StemBioSys Inc. has closed on $8 million in Series A preferred stock financing that the company will use to help launch its initial product — the HPME (High Performance Microenvironment) advanced stem cell culture system. San Antonio-based Targeted Technology Fund led the financing with an investment of $2.25 million. More than 50 angel investors also participated in the funding round.”

360 Newsletter Editor

Bernard Siegel
Executive Director
Genetics Policy Institute

Stem Cells and the Transformative Power of Hope-a TEDx talk by Bernard Siegel, Editor of 360 Newsletter

About GPI

The nonprofit Genetics Policy Institute (GPI) seeks to establish a positive policy, regulatory and societal framework to enable research to flourish, under the highest ethical and medical standards. We seek to accelerate the discovery and development of lifesaving cures and therapies to alleviate human suffering due to chronic and terminal afflictions. Visit Website.

ConnectGPI on FacebookGPI on TwitterGPI on LinkedIn

Genetics Policy Institute (GPI) and the Regenerative Medicine Foundation (RMF) Announce Merger Plan

Copyright © 2015 Genetics Policy Institute, All rights reserved.

Domain: Medical
Category: Biology

Recent Newsletters

12 March, 2019
10 October, 2018
15 February, 2018